Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Systemic treatment of vitiligo : Balance and current developments].

M Meurer1,2, P Ceric-Dehdari3

  • 1Stiftung zur Förderung der Hochschulmedizin in Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. michael.meurer@uniklinikum-dresden.de.

Der Hautarzt; Zeitschrift Fur Dermatologie, Venerologie, Und Verwandte Gebiete
|October 15, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteasome-dependent protein quality control of the peroxisomal membrane protein Pxa1p.

Biochimica et biophysica acta. Biomembranes·2020
Same author

[37-year-old male with confluent papules and arcuate erythematosquamous plaques on the upper trunk and arms : Preparation for the specialist examination: part 22].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2018
Same author

[In memory of Prof. Dr. med. Dr. h.c. mult. Otto Braun-Falco].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2018
Same author

[Pigmentation disorders].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2017
Same author

[Oculocutaneous and ocular albinism].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2017
Same author

[Treatment of vitiligo].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete·2016

New systemic treatments for vitiligo, including afamelatonide and Janus kinase (JAK) inhibitors, show promise. These therapies target inflammatory reactions and may expand treatment options beyond current UV light and topical therapies.

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Systemic drug treatment for vitiligo is primarily adjuvant to UV light therapy.
  • Current treatments focus on topical anti-inflammatory and UV therapies, often used in combination.

Purpose of the Study:

  • To present novel systemic treatment approaches for vitiligo currently under clinical investigation.
  • To explore the potential of new therapies to expand vitiligo treatment options.

Main Methods:

  • Investigating α‑MSH-analogue afamelatonide for systemic vitiligo treatment.
  • Examining oral immunosuppressants, specifically Janus kinase (JAK) inhibitors, targeting interferon-α-dependent inflammatory reactions.
  • Utilizing animal models and serum biomarker characterization to support treatment effectiveness.
Keywords:
ChemokinesImmunosuppressionInterferon-gammaJAK inhibitorsPhototherapy

Related Experiment Videos

Main Results:

  • Janus kinase (JAK) inhibitors have demonstrated successful systemic use in vitiligo since 2015.
  • Experimental evidence from animal models and biomarker studies supports the efficacy of these JAK inhibitors.
  • These advancements may significantly broaden the therapeutic landscape for vitiligo.

Conclusions:

  • Novel systemic therapies, including afamelatonide and JAK inhibitors, represent a significant advancement in vitiligo treatment.
  • These approaches target underlying inflammatory mechanisms, offering new hope for patients.
  • Future research and clinical trials are crucial to fully establish the role of these systemic treatments.